FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors

The FDA granted a priority review to Deciphera Pharmaceuticals ’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors.

Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news